Bala Cynwyd, PA – According to filings with the U.S. Securities and Exchange Commission, Larimar Therapeutics is raising $80,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Michael Celano played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Larimar Therapeutics

Larimar is dedicated to improving the ability of patients with rare diseases to pursue their dreams. Larimar Therapeutics is a clinical stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar Therapeutics also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

To learn more about Larimar Therapeutics, visit http://larimartx.com/

Contact:
Michael Celano, Chief Financial Officer
844-511-9056
https://www.linkedin.com/in/mike-celano-34059810/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved